Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6669)

VOLUNTARY ANNOUNCEMENT APPROVAL FOR PERIDGE® BY PRC NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Acotec Scientific Holdings Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the "Board") of the Company is pleased to announce that on January 30, 2024, the Company received the registration approval from the PRC National Medical Products Administration for the Peridge®, a Peripheral Scoring Balloon Dilatation Catheter, which is used for the treatment of stenotic lesions in autologous or synthetic arteriovenous fistulae for hemodialysis. Peridge® provides effective anchoring points and aids in the directed opening of lesions, reducing the incidence and severity of elastic recoil for plaques or proliferative intimal tissue and flow-limiting dissections while dilating the vessel lumen, thereby minimizing excessive vascular injury. This product can facilitate better vessel preparation for drug-coated balloons (DCB) treatment. The Company will carry out marketing activities in PRC market when appropriate.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET PERIDGE® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By Order of the Board

Acotec Scientific Holdings Limited

Jing LI

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, January 31, 2024

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.